Biblio

Author Title [ Type

] Year

Filters: Author is Beelen, Dietrich W [Clear All Filters]

Journal Article

Kordelas L, Steckel N-K, Horn PA, Beelen DW, Rebmann V. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease. Int J Mol Sci. 2016;17(11).

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.

Turki AT, Lamm W, Schmitt C, Bayraktar E, Alashkar F, Metzenmacher M, Wohlfarth P, Beelen DW, Liebregts T. Correction to: Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. Ann Hematol. 2018.

Bayraktar E, Graf T, Ayuk FA, Beutel G, Penack O, Luft T, Brueder N, Castellani G, H Reinhardt C, Kröger N, et al. Data-driven grading of acute graft-versus-host disease. Nat Commun. 2023;14(1):7799.

Kordelas L, Terzer T, Gooley TA, Davis C, Sandmaier BM, Sorror MLotfy, Penack O, Schaeper NDross Enge, Blau IW, Beelen DW, et al. EASIX-1 year and late mortality after allogeneic stem cell transplantation. Blood Adv. 2023.

Adam B, Koldehoff M, Ditschkowski M, Gromke T, Hlinka M, Trenschel R, Kordeals L, Steckel NK, Beelen DW, Liebregts T. Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease. Dig Dis Sci. 2016.

Bethge WAndreas, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EMaria, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.

Turki AT, Tsachakis-Mück N, Leserer S, Crivello P, Liebregts T, Betke L, Alashkar F, Leimkühler NBastian, Trilling M, Fleischhauer K, et al. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Adv. 2021.

Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.

Turki AT, Klisanin V, Bayraktar E, Kordelas L, Trenschel R, Ottinger H, Steckel NK, Tsachakis-Mück N, Leserer S, Ditschkowski M, et al. Optimizing anti-T-lymphocyte globuline dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. Am J Transplant. 2019.

Li X, Kalwak K, Beier R, Kehne J, Möller A-K, Baumgart J, Beelen DW, Hilger RA, Vora A, Sykora K-W. Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. Drug Metab Pharmacokinet. 2023;52:100515.